Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 101 to 110 of 471 total matches.

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
of all ages due to prolonged wearing of masks during the COVID-19 pandemic.1 Guidelines for treatment ...
Acne is common among adolescents and young adults, but its prevalence appears to have increased in people of all ages due to prolonged wearing of masks during the COVID-19 pandemic. Guidelines for treatment of acne were last published in 2016.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):188-91 | Show Introduction Hide Introduction

Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
in patients with severe active ulcerative colitis. Table 1. Sutab Clinical Trial Results Trial Regimen1 ...
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride (Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):33-6 | Show Introduction Hide Introduction

In Brief: Semglee - Insulin Glargine Interchangeable with Lantus

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
will be the same if the patient switches between the reference product and the biosimilar.1 In an open-label ...
Insulin glargine-yfgn (Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin product to receive this designation in the US. Now a pharmacist can substitute Semglee for Lantus as a lower-cost alternative without permission from the prescriber.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):159-60 | Show Introduction Hide Introduction

Eptinezumab (Vyepti) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
once monthly (fremanezumab can also be given once every 3 months), were approved earlier.1 ...
The FDA has approved eptinezumab-jjmr (Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):85-7 | Show Introduction Hide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • Oct 08, 2018  (Issue 1557)
methods generally have higher failure rates than other methods.1-3 COMBINATION ORAL CONTRACEPTIVES ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-8 | Show Introduction Hide Introduction

Jatenzo - An Oral Testosterone for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
. TESTOSTERONE REPLACEMENT — Oral testosterone replacement therapy has generally been ineffective Table 1. Some ...
An oral formulation of testosterone undecanoate (Jatenzo – Clarus) has been approved by the FDA for treatment of adult men with conditions associated with a deficiency of endogenous testosterone, such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Jatenzo is not approved for treatment of low testosterone levels solely due to aging. It is the first oral testosterone formulation to be approved in the US.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):103-4 | Show Introduction Hide Introduction

In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
mg per spray (Narcan) was approved in 2015.1 Pronunciation Key Kloxxado: kloks ah’ doh Table 1 ...
The FDA has approved a higher-dose intranasal naloxone formulation (Kloxxado – Hikma) for emergency treatment of opioid overdose. A single spray of the new formulation delivers 8 mg of naloxone; a formulation that delivers 4 mg per spray (Narcan) was approved in 2015.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):151-2 | Show Introduction Hide Introduction

In Brief: An Asenapine Patch (Secuado) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
1). Asenapine was also superior to placebo in the Clinical Global Impressions-Severity (CGI ...
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine (Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since 2009.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):7-8 | Show Introduction Hide Introduction

Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
hematopoietic cell transplant (HCT), which can be curative.1 MECHANISM OF ACTION — The antibody-drug ...
The FDA has approved inotuzumab ozogamicin (Besponsa – Pfizer), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It is the first CD22-directed antibody-drug conjugate to be approved in the US.
Med Lett Drugs Ther. 2018 May 21;60(1547):e90-1 | Show Introduction Hide Introduction

Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018  (Issue 1553)
Ciprofloxacin Otic Suspension Otiprio) for Acute Otitis Externa Table 1. Some Otic ...
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin (Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
Med Lett Drugs Ther. 2018 Aug 13;60(1553):135-6 | Show Introduction Hide Introduction